Atlanta, Georgia--(Newsfile Corp. - February 8, 2022) - Holzer & Holzer, LLC is investigating whether Pulse Biosciences, Inc. ("Pulse Biosciences" or the "Company") (NASDAQ: PLSE) complied with federal securities laws. On February 8, 2022, Pulse Biosciences provided an update on the Company's recent 510(k) submission, which added sebaceous hyperplasia as an indication for use to its CellFX System. In the announcement, the Company revealed it had "received an Additional Information ("AI") letter from the FDA . . . stat[ing] it did not believe the Company provided sufficient clinical evidence at this time to support the expanded indication for use, and that the Company had not met the primary endpoints of the sebaceous hyperplasia FDA-approved IDE study." Following the announcement, the Company's stock dropped.
If you purchased Pulse Biosciences stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.
CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/113173
